Latigo Biotherapeutics posted a $25,797,000 ($25.797 million) net loss for the quarter ended June 30, 2026, while cash and equivalents stood at $55,003,000 ($55.003 million). The figures matter to investors because the company plans to advance onzotrigine, LTG-321 and additional pain-treatment programs.
Key Highlights
- Cash and cash equivalents totaled $55,003,000 ($55.003 million) at June 30, 2026.
- Total current liabilities reached $51,575,000 ($51.575 million), including $29,897,000 ($29.897 million) in convertible promissory notes.
- Latigo identified onzotrigine and LTG-321 as its two most advanced candidates and said it is advancing additional Naᵥ1.8 candidates.
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) recorded a net loss of $25,797,000 ($25.797 million) for the quarter ended June 30, 2026. Research and Development costs declined as direct development costs fell, while personnel-related and other research expenses increased.
Research and Development Spending
Direct costs tied to onzotrigine and other clinical and non-clinical programs decreased during the period. The reduction was offset by higher personnel-related research and development expenses, which the company linked to increased headcount and stock-based compensation. Other research and development expenses also rose. General and administrative expenses increased. Latigo’s two most advanced candidates are oral Naᵥ1.8 inhibitors designed to inhibit pain transmission.
$55.003M Cash Balance
Cash and cash equivalents stood at $55,003,000 ($55.003 million) at June 30, 2026, compared with $69,437,000 ($69.437 million) at December 31, 2025. Restricted cash was $194,000, up from $192,000. Total current Assets were $59,199,000 ($59.199 million), compared with $73,829,000 ($73.829 million) at December 31, 2025. Total assets were $64,760,000 ($64.760 million), versus $75,516,000 ($75.516 million). Operating Lease right-of-use assets totaled $1,303,000 ($1.303 million), while property and equipment, net, stood at $457,000 ($0.457 million). Other assets were $3,801,000 ($3.801 million).
Current Liabilities and Convertible Notes
Current liabilities totaled $51,575,000 ($51.575 million), compared with $18,446,000 ($18.446 million) at December 31, 2025. Accounts Payable were $3,566,000 ($3.566 million), while accrued expenses and other current liabilities totaled $12,259,000 ($12.259 million). Convertible promissory notes accounted for $29,897,000 ($29.897 million) of current liabilities. A derivative Liability totaled $5,148,000 ($5.148 million). Total liabilities were $52,258,000 ($52.258 million), compared with $18,608,000 ($18.608 million) at December 31, 2025. Non-current operating lease liabilities were $648,000 ($0.648 million), and other long-term liabilities were $35,000 ($0.035 million). Redeemable convertible preferred stock totaled $288,582,000 ($288.582 million). The stock had a Par Value of $0.0001 per share, with 264,397,134 shares authorized and 41,155,082 shares issued and outstanding.
Pipeline Development
The company has not generated Revenue from product sales to date. The company is committed to developing non-opioid pain medicines designed to stop pain transmission without the risk of addiction. The filing discusses clinical and non-clinical development of the company’s pain candidates.




Please wait processing your request...